AnGes

Basic Information

Stock Code
4563
Industry
Pharmaceuticals
Category Detail
Biotechnology & Pharmaceuticals
Prefecture
Osaka Prefecture
Establishment Year
December 1999
Listing Year
September 2002
Official Website
https://www.anges.co.jp/
TSE Information
TSE Information
Yahoo! Finance
Yahoo! Finance
Other Companies
GNI Group, Heartseed, Nexel Pharma, SymBio, KaIOM, PeptiDream, SanBio, Helios, BrightPath, RenaScience, QualiPS, Takara Bio, Japan Tissue Engineering

Overview

AnGes is a bio-pharmaceutical venture originating from Osaka, founded in 1999, specializing in the research and development of gene medicines and possessing proprietary technologies both domestically and internationally.

Current Situation

AnGes focuses on the research and development of gene therapy drugs, and as of 2022, its flagship product is Collategene, Japan's first HGF gene therapy drug to receive conditional and time-limited manufacturing and marketing approval. Although sales in 2019 were approximately 330 million yen, R&D investments have squeezed profits, resulting in a substantial operating loss. It received about 7.5 billion yen in government subsidies for COVID-19 vaccine development but abandoned the project, and is continuing clinical trials for an improved vaccine over several years. Partnering with major domestic pharmaceutical companies and overseas biotech firms, it is advancing international joint trials toward the practical application of gene therapy technology. Through aggressive third-party allotment capital raises, it has secured funding to strengthen its R&D foundation. Moving forward, it aims to expand indications for gene medicines and develop new products. Since 2022, it has continued research activities based in Ibaraki City, Osaka Prefecture, striving to establish its position as a leading gene medicine development company.

Trivia

Interesting Facts

  • The company obtained Japan's first conditional manufacturing and marketing approval as a gene medicine.
  • It is a university-spun venture established based on research成果 from Osaka University School of Medicine.
  • HGF gene therapy drug Collategene is a pioneering gene therapy product in Japan.
  • It received massive government subsidies for COVID-19 vaccine development but ultimately abandoned it.
  • It holds a large patent portfolio based on the founders' research.
  • Numerous partnerships with domestic and international pharma and biotech companies strengthen its research base.
  • Headquartered at the Suita Bio-Incubator in Ibaraki City, promoting regional collaboration.
  • It also handles immune-modulating nucleic acid medicines and gene vaccines in product development.
  • It has previously received a Financial Services Agency order for insider trading disgorgement.
  • It has actively secured funding for R&D through multiple capital increases.
  • Representative Director Hideki Yamada is a highly specialized executive in gene therapy.
  • It conducts activities for overseas expansion, including international clinical trials for gene therapy drugs.
  • It is expected to practicalize as Japan's first gene therapy drug in the market.
  • It has received multiple public awards and venture prizes for R&D.
  • It changed its trade name the year after establishment to specialize in gene medicines.

Hidden Connections

  • Major pharmaceutical companies such as Shionogi & Co. are major shareholders with partnership relations.
  • Close technological collaboration with Takara Bio on joint COVID-19 vaccine development.
  • Possesses strong research network with founders and Osaka University's medical research division.
  • Aiming for global expansion of gene medicines through partnerships with overseas biotech firms.
  • Past Financial Services Agency insider trading investigation identified executives as key figures.
  • Receives support from specific local governments (Osaka Prefecture) to vitalize regional medical research.
  • Influencing establishment of multiple related companies and institutes using its own drug discovery technology.
  • Experience of Phase III trial discontinuation has informed strategic management decisions.

Future Outlook

Growth Drivers

  • Expansion of domestic market for gene therapy drugs and new disease indications
  • Acceleration of global rollout through international joint trials and development
  • Progress in nucleic acid medicines and gene vaccine technologies with broader applications
  • Tailwinds from strengthened government support policies for biopharma industry
  • Increasing demand for gene medical products amid rising healthcare needs
  • Cost reduction and quality improvement via advanced manufacturing technologies
  • Social demand for sustainable and ethical pharmaceutical development
  • Stabilized R&D base through enhanced fundraising capabilities
  • Sales channel expansion via strategic partnerships with pharmaceutical companies
  • Improved clinical development efficiency through digital technology utilization
  • Success in developing products balancing safety and efficacy
  • Strengthened product rollout in immune-related disease fields

Strategic Goals

  • Achieve 30% domestic market share in gene medicines
  • Practicalize gene therapy drugs with multiple indications
  • Obtain approvals and commence sales in major global markets
  • Realize clinical applications of innovative gene editing technology
  • Sustain R&D expense ratio above 20%
  • Establish sustainable manufacturing systems and reduce environmental impact
  • Build corporate culture respecting diversity and inclusion
  • Expand strategic partnerships with major domestic and international pharma companies
  • Successfully commercialize and launch gene vaccines
  • Strengthen regional collaborations and support next-generation talent development

Business Segments

Gene Medicine R&D Support

Overview
Comprehensive support for gene medicine R&D, providing cutting-edge technologies.
Competitiveness
Advanced gene technology portfolio unique to a university-spun biotech venture
Customers
  • Pharmaceutical Companies
  • University Research Institutions
  • Biotech Ventures
  • Government Grant Agencies
  • Clinical Trial Organizations
  • Research Partners
Products
  • Plasmid DNA Formulations for Gene Therapy
  • Nucleic Acid Medicine Development Support
  • Gene Vaccine Services
  • Joint Research and Development
  • Technology Licensing

Medical Gene Therapy Drug Supply

Overview
Supply and management of Japan's first conditionally approved gene therapy drug.
Competitiveness
Pioneering domestically produced gene therapy drug in the Japanese market
Customers
  • Hospitals
  • Clinics
  • Pharmaceutical Sales Agents
  • University Hospitals
  • Research Facilities
Products
  • Gene Therapy Drug Collategene
  • Related Pharmaceutical Materials
  • Therapeutic Plasmid DNA
  • Special Formulation Manufacturing
  • Quality Management Services

Gene Therapy Drug Clinical Trial Outsourcing

Overview
Clinical trial operations and application support services for gene therapy drugs.
Competitiveness
Integrated provision of clinical trial execution and regulatory know-how
Customers
  • Pharmaceutical Companies
  • Clinical Trial Hospitals
  • Academic Institutions
  • Clinical Development Organizations
Products
  • Clinical Trial Outsourcing Services
  • Data Analysis Support
  • Regulatory Approval Application Support

Gene Medicine Collaborative Development

Overview
Joint development of gene medicines in collaboration with domestic and international companies.
Competitiveness
Diverse international networks and technological capabilities
Customers
  • Domestic Pharmaceutical Companies
  • Overseas Biotech Firms
  • Venture Capital
Products
  • Biopharmaceutical Joint Research
  • Technology License Provision
  • Sales Partnerships

Research Materials Sales

Overview
Sales of materials for gene medicine research.
Competitiveness
High-quality products based on university-derived technology
Customers
  • Research Institutions
  • Universities
  • Pharmaceutical Companies
Products
  • Gene-Related Reagents
  • Plasmid DNA Products
  • Nucleic Acid Oligo Products

Pharmaceutical Technology Consulting

Overview
Technical consulting for gene medicine development.
Competitiveness
Expertise leveraging years of development experience
Customers
  • Biotech Ventures
  • Pharmaceutical Companies
  • Research Institutions
Products
  • Technology Transfer Support
  • Regulatory Compliance Guidance
  • Manufacturing Process Improvement

Intellectual Property Management & Licensing

Overview
Building and management of IP strategies related to gene medicines.
Competitiveness
IP portfolio based on founders' research achievements
Customers
  • Companies
  • R&D Institutions
Products
  • Patent Management
  • Licensing Agreements
  • Technology Negotiations

Biopharmaceutical Manufacturing Outsourcing

Overview
High-precision manufacturing services for gene formulations.
Competitiveness
Specialized GMP-compliant manufacturing capabilities
Customers
  • Pharmaceutical Companies
  • Biotech Ventures
Products
  • Plasmid DNA Manufacturing
  • Pharmaceutical Formulation
  • Quality Control Testing

Treatment Efficacy Evaluation Services

Overview
Technical support for evaluating the efficacy of gene therapy drugs.
Competitiveness
Analytical capabilities backed by gene medicine expertise
Customers
  • Pharmaceutical Companies
  • Medical Institutions
Products
  • Gene Therapy Effect Monitoring
  • Clinical Data Analysis

Education and Awareness Activities

Overview
Support for promoting understanding of gene therapy.
Competitiveness
Comprehensive educational system in collaboration with experts
Customers
  • Healthcare Professionals
  • Patient Groups
  • Researchers
Products
  • Seminars
  • Awareness Materials Creation
  • Patient Support Programs

New Treatment Technology Development

Overview
Advancement of drug discovery R&D for cutting-edge technologies.
Competitiveness
Innovative technological prowess and diverse academic collaborations
Customers
  • Research Institutions
  • Medical Ventures
Products
  • Gene Delivery Technology
  • Nucleic Acid Medicine Technology
  • Gene Editing Tools

Competitive Advantage

Strengths

  • Possesses advanced gene technology from university origins
  • Track record of Japan's first gene therapy drug approval
  • Experience in international joint clinical trials
  • Proven partnerships with major pharmaceutical companies
  • Abundant specialized R&D personnel
  • Strong and stable fundraising capabilities
  • Proprietary gene medicine platform
  • Close collaboration with medical sites
  • Technological superiority in gene medicine field
  • Accumulated know-how in clinical development and regulatory submissions
  • Robust systems for domestic and international regulatory compliance
  • Research expansion into diverse indications
  • High R&D investment ratio
  • High-quality manufacturing technology
  • Ability to secure public funding support

Competitive Advantages

  • Maintains domestically leading R&D capabilities in gene medicines
  • Establishes market superiority with track record of conditional approval
  • Accelerates development through international networks and joint trials
  • Diversifies future revenue base with broad product pipeline
  • Innovative drug creation power from university-derived technology base
  • Complements sales and technology strengths via partnerships with major pharma
  • Enables long-term R&D with strong fundraising record
  • Strong portfolio of intellectual property including patents
  • Superior clinical development and regulatory capabilities for swift market entry
  • Integration of next-generation technologies like gene vaccines and nucleic acid medicines
  • Continuous technological innovation via regional R&D hubs
  • Enhanced reliability through accumulated clinical evidence of treatment efficacy
  • Strong relationships with healthcare professionals and patient communities
  • Differentiation from competitors via advanced gene delivery technology
  • Proven ability to secure support from MHLW and other public institutions

Threats

  • Risk of market entry failure due to insufficient efficacy of new treatments
  • Acceleration of innovative biopharma development by competitors
  • Risk of approval delays from changes in international regulations
  • Uncertainty in securing development funds and market environment shifts
  • Challenges in recruiting clinical trial subjects
  • Potential concerns over IP infringement or disputes
  • Social concerns regarding safety issues in gene therapy
  • Risk of non-performance by partnership collaborators
  • Intensifying price competition in the market
  • Potential technical failures in emerging infectious disease responses
  • Impact of policy changes on medical insurance reimbursements
  • Supply chain disruptions and quality issues

Innovations

2022: Announcement of Discontinuation of COVID-19 Vaccine Development

Overview
Development discontinued as it failed to achieve expected efficacy levels despite ensuring safety.
Impact
Enables reallocation of research resources

2021: Initiation of Clinical Trials for Improved DNA Plasmid Vaccine

Overview
Started clinical trials for an improved COVID-19 vaccine and is verifying efficacy.
Impact
Strengthens foundation for mid- to long-term product development

2020: Joint Development of COVID-19 DNA Vaccine

Overview
Rapid development of DNA plasmid-based vaccine in collaboration with Takara Bio.
Impact
Acquires infectious disease vaccine development technology

2020: Obtained Conditional Approval for Japan's First Gene Therapy Product

Overview
Received conditional approval for Collategene Intramuscular Injection 4mg for severe ischemic limbs.
Impact
Becomes pioneer in Japan's gene medicine market

2021: Decision to Discontinue International Joint Phase III Trials in US and Europe

Overview
Announced discontinuation of overseas Phase III trials due to difficulties in patient recruitment.
Impact
Review of clinical development strategy

2023: Advancing Research to Expand Indications for HGF Gene Therapy Drug

Overview
Exploring expansion into new disease areas based on clinical trial data.
Impact
Expectations for future product expansion and revenue growth

2024: Research to Expand Indications for Nucleic Acid Medicine AMG0101

Overview
Strengthening investigations for application in immune-inflammatory diseases.
Impact
Contributes to potential market expansion

2022: Platform Enhancement for Gene Therapy Technology

Overview
Improving delivery efficiency and safety through introduction of new technologies.
Impact
Builds foundation for next-generation product development

2023: Market Expansion Strategy via Strengthened Overseas Partnerships

Overview
Promoting sales channel expansion through partnerships with companies in multiple countries.
Impact
Expectations for increased overseas sales ratio

2024: Launch of Next-Generation Gene Therapy Drug Development Project

Overview
Initiating new drug creation using the latest gene editing technology.
Impact
Prepares for market launch of innovative therapies

Sustainability

  • Formulation of ethical policies prioritizing safety in gene medicines
  • Development of research environment through regional collaborations
  • Diversity-respecting talent recruitment and development
  • Enhanced transparency and disclosure in fundraising
  • Manufacturing processes designed to reduce environmental impact
  • Active participation in social contribution activities
  • Advanced management and safety assurance for medical information
  • Advancement of R&D for emerging infectious disease countermeasures
  • Appropriate utilization of public research grants
  • Internal compliance strengthening measures